



FY2023 Financial Results



3 new drug approvals

from the U.S. FDA

And **multiple life-cycle management approvals** in FY2023



Revenue

¥4,263.8_B

+1.5% growth at CER

+5.9% growth at AER



Core Operating Profit

¥1,054.9B

-13.3% change at Constant Exchange Rate (CER) / -11.2% at Actual Exchange Rate (AER) reflects generic impact and increased investment in R&D and data & technology

Core Operating Profit Margin

24.7%

Reported Operating Profit

¥214.1B

-56.4% change at Actual Exchange Rate impacted by non-core items



Our extensive portfolio of Growth & Launch Products continued to drive revenue growth.

43%

Share of Total Revenue

+12.8%

Growth at CER



50 million doses of dengue vaccine to be manufactured per year in partnership with Biological E. Ltd.

Accelerating our goal to manufacture **100 million** doses per year by 2030



Up to **6** potential new therapies
expected in Phase 3 development in FY2024



FY2024 Full-Year Outlook

Continued momentum of Growth & Launch Products expected to mitigate remaining loss of exclusivity headwinds

Core Revenue

¥4,350.0B

Core Operating Profit

¥1,000.0B

Core EPS

¥431

Management Guidance at CER

Core Revenue

Flat to slightly declining

Core Operating Profit

Approximately 10% decline

Core EPS

Mid-10s% decline





This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2023 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2023 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.